Collegium (COLL) Q1 2026: Jornay PM Revenue Climbs 36%, ADHD Portfolio Set for Acceleration
Collegium’s ADHD franchise delivered standout growth, with Jornay PM prescriptions and revenue sharply outpacing the pain portfolio. The pending Astaris acquisition positions the company for a step-change in ADHD market share and revenue longevity. Management’s focus on targeted commercial investments and portfolio diversification signals a multi-year growth runway, but integration and execution risks will be in focus as the Astaris deal closes.
Summary
- ADHD Franchise Momentum: Jornay PM’s rapid growth and new prescriber highs reinforce the brand’s differentiation and market potential.
- Portfolio Diversification: The Astaris acquisition is set to expand ADHD reach and extend revenue durability into the next decade.
- Execution Watchpoint: Integration of Astaris and continued pain portfolio resilience are critical for sustaining financial outperformance.
Business Overview
Collegium Pharmaceutical is a diversified biopharmaceutical company focused on treating serious medical conditions, with core franchises in ADHD (Attention Deficit Hyperactivity Disorder) and pain management. The company generates revenue from branded and authorized generic medicines, including Jornay PM, a once-daily evening-dosed ADHD stimulant, and a portfolio of pain treatments led by Belbuca, Xtampza ER, and Nucynta ER. Collegium’s business model leverages targeted commercial infrastructure and strategic acquisitions to drive growth, cash flow, and portfolio durability.
Performance Analysis
Collegium’s Q1 2026 results highlight the growing contribution of its ADHD franchise, with Jornay PM net revenue up 36% year-over-year and prescriptions rising 14%. The brand’s prescriber base expanded to a new high of approximately 30,000, up 17%, reflecting the impact of expanded sales force and digital marketing investments. The pain portfolio, which remains the company’s financial backbone, showed modest but steady growth, with both Belbuca and Xtampza ER posting year-over-year revenue gains, while Nucynta franchise revenues were stable despite generic pressures.
Operating cash flow remained robust at $57.1 million, supporting a strong cash position of $421.8 million. Management flagged that higher operating expenses reflect full-year impact of ADHD commercial investments, which are expected to yield continued prescription growth. The company’s capital deployment strategy remains balanced, with disciplined business development, debt repayment, and share repurchases all active levers.
- ADHD Prescription Expansion: Jornay PM’s 14% prescription growth outpaced the overall stimulant market, with both pediatric and adult segments contributing.
- Pain Portfolio Durability: Net revenue from pain products rose 4% year-over-year, providing stable cash flow to fund growth initiatives.
- Operating Leverage: Adjusted EBITDA grew in line with revenue, as gross-to-net ratios and payer strategies supported profitability.
The company’s ability to drive top-line growth while maintaining strong cash generation positions it well for the upcoming Astaris integration and further portfolio investments.
Executive Commentary
"The addition of Astaris accelerates our growth trajectory by strengthening our position in ADHD, complementing Jornay PM, and extending revenues into the late 2030s. This strategic acquisition reinforces our longstanding commitment to improving patient care while delivering long-term shareholder value."
Vikram Karnani, President and Chief Executive Officer
"We plan to fund the acquisition through a combination of $350 million in cash on hand, a testament to the strength of our underlying business, and $300 million from our delayed draw term loans. We estimate that our net debt to adjusted EBITDA will be approximately two times following the close of the transaction, and our future cash flows from operations will continue to support continued rapid de-levering."
Colleen Tupper, Chief Financial Officer
Strategic Positioning
1. ADHD Franchise Expansion
Collegium’s core strategic lever is its ADHD portfolio, led by Jornay PM and soon to be joined by Astaris. Both brands are differentiated—Jornay for its evening dosing and efficacy upon awakening, and Astaris for rapid and durable effect—enabling coverage of distinct patient needs. Management is leveraging targeted commercial investments, including increased sales force and digital campaigns, to drive awareness and prescriber intent.
2. Pain Portfolio Cash Generation
The pain franchise remains a critical source of cash and earnings stability. Collegium’s approach to lifecycle management, including authorized generics and payer-focused pricing strategies, is designed to maximize the value of legacy products while funding growth in ADHD and new business development.
3. Capital Deployment and M&A Discipline
The proposed $650 million Astaris acquisition is a pivotal move to extend revenue visibility and addressable market size. The company’s disciplined approach—funding the deal through a mix of cash and debt while maintaining a manageable leverage ratio—underscores a focus on sustainable growth and shareholder returns. Management also maintains flexibility for opportunistic share repurchases and future business development.
4. Commercial Infrastructure Leverage
Collegium’s ability to efficiently scale its ADHD commercial infrastructure is a core competitive advantage. The company plans to integrate Astaris into the existing sales force, driving cost synergies and operational efficiency while broadening prescriber reach. This infrastructure is designed to support both breadth and depth of physician engagement, with coverage optimized for high-volume prescribers.
5. Portfolio Longevity and Patent Protection
The Astaris acquisition extends Collegium’s ADHD revenue runway into 2037, backed by six Orange Book patents. This move insulates the business from near-term patent cliffs and provides a platform for further expansion, either within ADHD or in adjacent CNS indications.
Key Considerations
Collegium’s Q1 2026 performance and strategic actions set the stage for a pivotal year, but execution risks and market dynamics remain front of mind for investors.
Key Considerations:
- Integration Complexity: Seamless integration of Astaris into the ADHD commercial platform is critical to realizing revenue and cost synergies.
- ADHD Market Dynamics: Both brands face evolving competition, including potential new drug classes and shifting payer requirements.
- Pain Portfolio Maturity: While pain revenues are stable, generic pressures and volume declines could accelerate, testing the durability narrative.
- Capital Allocation Discipline: Management’s track record in M&A and share repurchases will be scrutinized as leverage rises post-Astaris.
Risks
Key risks include integration challenges with Astaris, competitive threats from new ADHD entrants (such as orexin agonists), and the ongoing erosion of the pain portfolio from generics. Payer access and reimbursement changes could impact both ADHD and pain franchises, while rising operating expenses from commercial investments must translate into sustainable top-line growth to avoid margin compression. Management’s guidance assumes stable market dynamics, but any disruption in ADHD adoption or pain portfolio pricing would pressure results.
Forward Outlook
For Q2 2026, Collegium expects:
- Continued growth in Jornay PM prescriptions and revenue, driven by expanded commercial reach and new marketing initiatives.
- Integration of Astaris, with anticipated immediate accretion to adjusted EBITDA and over $50 million in pro forma net revenues in the second half of 2026.
For full-year 2026, management reaffirmed guidance (excluding Astaris):
- Total product revenues of $805 to $825 million.
- Jornay PM revenue of $190 to $200 million, a 31% year-over-year increase at the midpoint.
- Adjusted EBITDA of $455 to $475 million.
Management cited confidence in ADHD growth, pain portfolio durability, and rapid deleveraging post-Astaris as key outlook drivers.
- ADHD franchise growth and successful Astaris integration are the primary growth engines.
- Continued cash generation from pain products will fund further business development and capital returns.
Takeaways
Collegium’s Q1 2026 results validate its ADHD growth thesis, but the next phase hinges on flawless execution as the Astaris acquisition closes and the competitive landscape evolves.
- Prescription Growth as Lead Indicator: Jornay PM’s double-digit prescription and revenue gains highlight effective commercial execution and brand differentiation.
- Portfolio Strategy in Action: The Astaris deal is a bold bet on ADHD, with management leveraging cash flow and commercial infrastructure to pursue multi-year growth and revenue durability.
- Execution and Integration Watch: Investors should monitor the pace and quality of Astaris integration, as well as any signs of generic or competitive disruption in the pain and ADHD markets.
Conclusion
Collegium enters the remainder of 2026 with momentum in ADHD and a clear path to portfolio diversification and cash flow resilience. The coming quarters will test management’s ability to integrate Astaris, sustain ADHD outperformance, and defend the pain franchise, but the strategic foundation for multi-year growth is in place.
Industry Read-Through
Collegium’s results reinforce the importance of commercial differentiation and lifecycle management in specialty pharma. The company’s targeted investments in sales force expansion and digital outreach for ADHD brands are delivering tangible share gains, suggesting that commercial agility and brand positioning remain decisive in crowded therapeutic areas. The Astaris acquisition also spotlights a broader industry trend: portfolio consolidation and patent extension as levers to offset generic erosion and market maturity. Peers in CNS and pain management should note Collegium’s disciplined capital deployment and commercial integration playbook, as the sector continues to prioritize cash-generating assets and multi-brand platforms to sustain growth in the face of evolving payer and competitive dynamics.